TOXYLACT: a03ae summary

The first professional lActological database in the word

This web-page monograph summarizes the toxicological and lactation-related characteristics of drugs classified under ATC A03AE (drugs acting on serotonin receptors in the gastrointestinal tract), with a focus on alosetron, tegaserod, cilansetron and prucalopride.medpedia.framar+3

Pharmacological class overview

ATC group A03AE comprises drugs acting on serotonin (5‑HT) receptors that modulate gastrointestinal motility and visceral sensitivity, used mainly for functional bowel disorders such as irritable bowel syndrome (IBS) and chronic constipation.pubmed.ncbi.nlm.nih+3
Alosetron and cilansetron are selective 5‑HT3 receptor antagonists, whereas tegaserod and prucalopride are 5‑HT4 receptor agonists with prokinetic properties that accelerate colonic transit and improve constipation‑related symptoms.drugbank+3
These medicines influence serotonin‑mediated pathways in the enteric nervous system, altering visceral pain perception, bowel habits, and motility, which explains both their therapeutic benefits and characteristic adverse reaction profiles.scienceopen+2

Individual agents and key toxicology

Alosetron (A03AE01) is an oral, highly selective 5‑HT3 receptor antagonist indicated for severe diarrhoea‑predominant IBS in women, modulating serotonin‑sensitive gastrointestinal processes and reducing urgency and stool frequency.drugbank+1
Its toxicity profile is dominated by serious gastrointestinal adverse events, notably constipation, complications of severe constipation, and rare but important cases of ischaemic colitis, which led to strong prescribing restrictions in many markets.pmc.ncbi.nlm.nih+1
Cilansetron (A03AE03) is another potent 5‑HT3 antagonist developed for IBS; like alosetron, it reduces activation of extrinsic afferent neurons and may decrease visceral pain, but concerns about ischaemic colitis and serious gastrointestinal events have limited its development and regulatory approval.scienceopen+1

Tegaserod (A03AE02) is a partial 5‑HT4 receptor agonist that enhances peristalsis, accelerates colonic transit and relieves constipation‑predominant IBS symptoms, especially abdominal discomfort and bloating.scielo+3
Common adverse effects include diarrhoea and headache; serious cardiovascular safety signals observed post‑marketing led to temporary withdrawals or restricted indications despite generally favourable tolerability in clinical trials.sciencedirect+2
Prucalopride (A03AE04) is a high‑affinity, highly selective 5‑HT4 agonist used for chronic idiopathic constipation in adults, shown to improve stool frequency and patient‑reported outcomes while avoiding significant off‑target cardiovascular effects seen with older non‑selective prokinetics.pmc.ncbi.nlm.nih+2

Across the A03AE class, dose‑related gastrointestinal adverse reactions such as diarrhoea, abdominal pain, nausea and constipation are frequent, and rare serious events like ischaemic colitis (with 5‑HT3 antagonists) or cardiovascular events (with some 5‑HT4 agonists) warrant careful risk assessment and patient selection.journals.sagepub+2
These agents should be reserved for patients with clearly established functional bowel disorders who have not responded adequately to conventional therapies, and used under close monitoring for gastrointestinal and cardiovascular toxicity.pubmed.ncbi.nlm.nih+2

Lactation (breastfeeding) considerations

Data on use of alosetron, tegaserod and cilansetron during breastfeeding are extremely limited, and no robust human milk pharmacokinetic studies have been published for these agents.gpnotebook+1
Given their systemic absorption, potential for serious gastrointestinal adverse effects, and lack of lactation safety data, use of 5‑HT3 antagonists (alosetron, cilansetron) and tegaserod during breastfeeding is generally discouraged; if considered, it should be restricted to exceptional situations with specialist input and careful infant monitoring.sps+4

Prucalopride has the most specific lactation data in this group: limited studies show that it is excreted into breast milk, with an estimated infant dose of around 6% of the maternal weight‑adjusted dose, suggesting relatively low exposure.droracle+2
UK specialist guidance and clinical pharmacology sources state that prucalopride can be used during breastfeeding with caution, preferably after other laxatives have been tried, with observation of the infant for changes in bowel habit, feeding and weight gain.gpnotebook+2
Overall, safer alternatives (osmotic or bulk‑forming laxatives with negligible systemic absorption) are usually preferred during lactation, and serotonin‑modulating A03AE drugs should be reserved for situations where maternal benefit clearly outweighs theoretical infant risks.sps+1

Clinical toxicology‑lactology guidance

When considering A03AE drugs in women of childbearing age, pre‑treatment counselling should cover potential serious gastrointestinal and cardiovascular toxicities, the need to stop therapy promptly if alarming symptoms (severe abdominal pain, rectal bleeding, chest pain) occur, and the limited evidence base for use in pregnancy and lactation.pmc.ncbi.nlm.nih+3
In breastfeeding women, non‑serotonergic laxatives and non‑pharmacological measures (dietary fibre, hydration, physical activity) remain first‑line; prucalopride may be an option with caution if chronic constipation is refractory, whereas alosetron, tegaserod and cilansetron should generally be avoided due to serious toxicity concerns and absent lactation data.drugbank+4
Individual risk–benefit assessment, collaboration between gastroenterologist and lactation‑aware pharmacist, and documentation of informed consent are essential when any A03AE drug is used in a breastfeeding patient.droracle+1

Recent Posts

July 24

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

July 18

Abdominal Compartment Syndrome

While the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 14

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.